[1] SUNG H, FERLAY J, SIEGELR L, et al. Global cancer statistics 2020: GLOBOCANestimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi:  10.3322/caac.21660
[2] RAWLA P, SUNKARA T, BARSOUK A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors[J]. Prz Gastroenterol, 2019, 14(2):89-103.
[3] KIMJ Y, HE F, KARIN M. From liver fat to cancer: perils of the western diet[J]. Cancers, 2021, 13(5):1095. doi:  10.3390/cancers13051095
[4] JIA F J, YU Q, WANG R L, et al. Optimized antimicrobial peptide jelleine-I derivative Br-J-I inhibits Fusobacterium nucleatum to suppress colorectal cancer progression[J]. Int J Mol Sci, 2023, 24(2):1469. doi:  10.3390/ijms24021469
[5] BENSONA B, VENOOK A P, AL-HAWARY M M, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2021, 19(3):329-359.
[6] KELLAND L. The resurgence of platinum-based cancer chemotherapy[J]. Nat Rev Cancer, 2007, 7(8):573-584. doi:  10.1038/nrc2167
[7] WALKOC M, LINDLEY C. Capecitabine: a review[J]. Clin Ther, 2005, 27(1):23-44. doi:  10.1016/j.clinthera.2005.01.005
[8] CHU D K, ZHANG Z X, LI Y M, et al. Prediction of colorectal cancer relapse and prognosis by tissue mRNA levels of NDRG2[J]. Mol Cancer Ther, 2011, 10(1):47-56. doi:  10.1158/1535-7163.MCT-10-0614
[9] DAHAN L, SADOK A, FORMENTOJ L, et al. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines[J]. Br J Pharmacol, 2009, 158(2):610-620. doi:  10.1111/j.1476-5381.2009.00341.x
[10] FAÏS T, DELMAS J, COUGNOUX A, et al. Targeting colorectal cancer-associated bacteria: a new area of research for personalized treatments[J]. Gut Microbes, 2016, 7(4):329-333. doi:  10.1080/19490976.2016.1155020
[11] HARUKI K, KOSUMI K, HAMADA T, et al. Association of autophagy status with amount of Fusobacterium nucleatum in colorectal cancer[J]. J Pathol, 2020, 250(4):397-408. doi:  10.1002/path.5381
[12] CHEN Y Y, CHEN Y, ZHANG J X, et al. Fusobacterium nucleatum promotes metastasis in colorectal cancer by activating autophagy signaling via the upregulation of CARD3 expression[J]. Theranostics, 2020, 10(1):323-339. doi:  10.7150/thno.38870
[13] MÁRMOL I, SÁNCHEZ-DE-DIEGO C, PRADILLADIESTE A, et al. Colorectal carcinoma: ageneral overview and future perspectives in colorectal cancer[J]. Int J Mol Sci, 2017, 18(1):197. doi:  10.3390/ijms18010197
[14] GUO S H, CHEN J, CHEN F F, et al. Exosomes derived from Fusobacterium nucleatum-infected colorectal cancer cells facilitate tumour metastasis by selectively carrying miR-1246/92b-3p/27a-3p and CXCL16[J]. Gut, 2020: gutjnl-gu2020-321187.
[15] XUE Y, XIAO H, GUO S H, et al. Indoleamine 2, 3-dioxygenase expression regulates the survival and proliferation of Fusobacterium nucleatum in THP-1-derived macrophages[J]. Cell Death Dis, 2018, 9(3):355. doi:  10.1038/s41419-018-0389-0
[16] BROOK I. Fusobacterial infections in children[J]. Curr Infect Dis Rep, 2013, 15(3):288-294. doi:  10.1007/s11908-013-0340-6
[17] COCHRANE K, ROBINSONA V, HOLTR A, et al. A survey of Fusobacterium nucleatum genes modulated by host cell infection[J]. Microb Genom, 2020, 6(2):e000300.
[18] HASHEMI GORADEL N, HEIDARZADEH S, JAHANGIRI S, et al. Fusobacterium nucleatum and colorectal cancer: a mechanistic overview[J]. J Cell Physiol, 2019, 234(3):2337-2344. doi:  10.1002/jcp.27250
[19] KOSTICA D, CHUN E, ROBERTSON L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment[J]. Cell Host Microbe, 2013, 14(2):207-215. doi:  10.1016/j.chom.2013.07.007
[20] HUI B Q, ZHOU C C, XU Y T, et al. Exosomes secreted by Fusobacterium nucleatum-infected colon cancer cells transmit resistance to oxaliplatin and 5-FU by delivering hsa_circ_0004085[J]. J Nanobiotechnology, 2024, 22(1):62. doi:  10.1186/s12951-024-02331-9